Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1812296 | 0.81 | HSD11B1 (0.82) | HSD11B1CA1CA2CA5ACA9 | |
| SCHEMBL27736519 | 0.80 | HSD11B1 (0.61) | HSD11B1CA1CA2CA5ACA9 | |
| SCHEMBL6050906 | 0.79 | CA1 (0.56) | HSD11B1CA1CA2CA5ACA9 | |
| SCHEMBL4973441 | 0.79 | CA1 (0.56) | HSD11B1CA1CA2CA5ACA9 | |
| SCHEMBL16046946 | 0.79 | CA1 (0.56) | HSD11B1CA1CA2CA5ACA9 | |
| SCHEMBL445417 | 0.79 | CA1 (0.56) | HSD11B1CA1CA2CA5ACA9 | |
| SCHEMBL439543 | 0.79 | CA1 (0.60) | HSD11B1CA1CA2CA5ACA9 | |
| SCHEMBL522267 | 0.78 | TDP1 (0.52) | HSD11B1CA1CA2CA5ACA9 | |
| SCHEMBL1816134 | 0.78 | CYP19A1 (0.55) | HSD11B1CA1CA2CA5ACA9 | |
| SCHEMBL16141195 | 0.77 | CA1 (0.58) | HSD11B1CA1CA2CA5ACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7419984-B2 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20040204386-A1 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204386-A1 | Pyrimidines and uses thereof | LPCAT3, LPCAT1, APRT | HSD11B1 3786/4885CA1 4588/4885CA2 4385/4885 |
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | LPCAT3, LPCAT1, APRT | HSD11B1 3125/4885CA1 4687/4885CA2 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.